(Q37218274)

19 August 2017

TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients (English)

1 reference

19 August 2017

Bon Ham Yip

3

0 references

Andrea Pellagatti

Andrea Pellagatti

4

0 references

Jacqueline Boultwood

Jacqueline Boultwood

20

0 references

Alan F List

Alan F List

21

0 references

Rami S Komrokji

19

Rami S Komrokji

1 reference

19 August 2017

12

Ashley Basiorka

1 reference

19 August 2017

2

Kathy McGraw

1 reference

19 August 2017

17

Lubomir Sokol

1 reference

19 August 2017

1

Gisela Caceres

1 reference

19 August 2017

Joseph Johnson

5

1 reference

19 August 2017

Ling Zhang

6

1 reference

19 August 2017

Kenian Liu

7

1 reference

19 August 2017

Lan Min Zhang

8

1 reference

19 August 2017

William J Fulp

9

1 reference

19 August 2017

Ji-Hyun Lee

10

1 reference

19 August 2017

Najla H Al Ali

11

1 reference

19 August 2017

Larry J Smith

13

1 reference

19 August 2017

F Joseph Daugherty

14

1 reference

19 August 2017

Neil Littleton

15

1 reference

19 August 2017

Richard A Wells

16

1 reference

19 August 2017

Sheng Wei

18

1 reference

19 August 2017

language of work or name

English

0 references

publication date

16 September 2013

1 reference

Proceedings of the National Academy of Sciences of the United States of America

19 August 2017

1 reference

19 August 2017

110

1 reference

19 August 2017

40

1 reference

19 August 2017

16127-16132

1 reference

New therapeutics for myelodysplastic syndromes.

19 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3791697

Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemia

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3791697

Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3791697

Dexamethasone and lenalidomide have distinct functional effects on erythropoiesis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3791697

Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3791697

New insights into 5q- syndrome as a ribosomopathy.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3791697

A small molecule inhibitor of p53 stimulates amplification of hematopoietic stem cells but does not promote tumor development in mice

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3791697

RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3791697

A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3791697

GATA-1 associates with and inhibits p53.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3791697

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3791697

Biological and prognostic significance of chromosome 5q deletions in myeloid malignancies

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3791697

Regulation of HDM2 activity by the ribosomal protein L11

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3791697

Potential roles of antisense oligonucleotides in cancer therapy. The example of Bcl-2 antisense oligonucleotides

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3791697

The p53 tumour suppressor inhibits glucocorticoid-induced proliferation of erythroid progenitors.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3791697

Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3791697

TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis.

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3791697

Effects of L-leucine in 5q- syndrome and other RPS14-deficient erythroblasts.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3791697

TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3791697

Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3791697

Oligonucleotide enhanced cytotoxicity of Idarubicin for lymphoma cells

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3791697

Myelodysplastic syndromes

3 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1073%2FPNAS.1311055110

Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1073%2FPNAS.1311055110

Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24043769

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Narrowing and genomic annotation of the commonly deleted region of the 5q- syndrome

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24043769

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1073/PNAS.1311055110

1 reference

release_f4zsdafbxrdthnozd66h2xqoly

19 August 2017

0 references

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/f4zsdafbxrdthnozd66h2xqoly

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

19 August 2017

PubMed publication ID

24043769

1 reference